Novo Nordisk A/S (NVO)

NYQ – Real Time Price. Currency in USD

47.00

+0.60 (1.29%)

At close: May 12, 2026, 4:00 PM EDT

47.09

+0.11 (0.23%)

Pre-market: May 13, 2026, 8:24 AM EDT

13.05.2026

Novo Nordisk A/S Q1 Earnings Call Highlights

Novo Nordisk A/S NYSE: NVO said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipeline and regulatory milestones, even as adjusted sales declined because of lower realized prices.

13.05.2026

Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026

Almost a third of adults taking Wegovy® pill (oral semaglutide 25 mg) were early responders to treatment, achieving an average of 13.2% weight loss after four months and 21.6% weight loss at the end of the OASIS 4 clinical trial1. Nearly eight in 10 people with poor physical function who took the Wegovy® pill almost doubled their ability to move, including bending over, standing comfortably and staying active, compared to placebo2.

12.05.2026

Novo Nordisk Presents New Wegovy Data Showing Strong Weight Loss, Fat Reduction

Novo Nordisk A/S (NYSE:NVO) presented new sub-analyses from its STEP UP clinical trial at the European Congress on Obesity, highlighting that a higher dose of Wegovy helped people with obesity achieve substantial weight loss regardless of how quickly they initially responded to treatment.

12.05.2026

GLP-1 Wars: Winners & Losers

With its best-in-breed GLP-1 drugs, Eli Lilly is beginning to cement itself as the dominant player in the massive GLP-1 market.

12.05.2026

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 12 May 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk.

12.05.2026

Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

12.05.2026

Healthy Returns: Novo Nordisk says high-dose Wegovy helped some patients lose nearly 28% of their weight

Novo Nordisk released new data that could help boost the case for the higher dose version of its blockbuster obesity injection Wegovy.

Videos

10.05.2026

Positive

AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

06.05.2026

Positive

Novo Nordisk CEO: Open to deals, we need the broadest pipeline in the world

06.05.2026

Positive

Novo Nordisk beats profit forecasts on bumper Wegovy pill sales

06.05.2026

Positive

Novo Raises Forecast as Wegovy Pill Fuels Sales

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
NVO	Wolfe Research	Peer Perform	undefined >> undefined	March 26th 2026
NVO	Bernstein	Outperform	undefined >> $175	March 18th 2026
NVO	TD Cowen	Hold	undefined >> $42	March 10th 2026
NVO	Morgan Stanley	Equal Weight	undefined >> $40	March 3rd 2026
NVO	Goldman	Neutral	undefined >> $41	March 2nd 2026
NVO	JP Morgan	Neutral	undefined >> undefined	February 24th 2026
NVO	Kepler	Hold	undefined >> undefined	February 24th 2026
NVO	Deutsche Bank	Hold	undefined >> undefined	February 23rd 2026

Press releases

13.05.2026

Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026

12.05.2026

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

12.05.2026

Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity

Wegovy® showed an average 22.6% weight loss for premenopausal women with obesity, with more than 4 in 10 (41.4%) achieving 25% or more weight loss1. Substantial weight loss was consistent across all menopausal stages, as well as major reductions in waist circumference, a key indicator of metabolic health1.

12.05.2026

Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity

Early responders (15% or more weight loss after 24 weeks) to the higher dose of Wegovy ® (semaglutide 7.2 mg) achieved on average 27.7% mean weight loss at week 72 in the STEP UP trial1 Participants treated with the higher dose of Wegovy ® reached weight loss goals faster as compared to semaglutide 2.4 mg1 The majority of the weight loss comes from losing body fat: 84% of weight loss with Wegovy ® (semaglutide 2.4 and 7.2 mg) can be attributed to reductions in fat mass, while preserving muscle function and improving muscle health2 Bagsværd, Denmark, 12 May 2026 – Novo Nordisk is presenting a new sub-analysis from the large clinical trial STEP UP at the European Congress on Obesity (ECO) on 12-15 May in Istanbul, Türkiye, showing that the higher dose of the weight loss drug Wegovy ® is highly effective at helping people with obesity lose significant amounts of weight regardless of how quickly their body responds to the treatment1. Moreover, a separate STEP UP sub-analysis presented at ECO shows that most of the weight loss with Wegovy ® was coming from body fat, and most of the muscle mass was kept2.

Novo Nordisk A/S (NVO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Novo Nordisk A/S (NVO)

Novo Nordisk A/S Q1 Earnings Call Highlights

Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026